Ingmar A F M Heijnen
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
Oechtering J, Lincke T, Schaedelin S, Décard B, Maceski A, Orleth A, Meier S, Willemse E, Buchmann A, Khalil M, Derfuss T, Benkert P, Heijnen I, Regeniter A, Müller S, Achtnichts L, Lalive P, Salmen A, Pot C, Gobbi C, Kappos L, Granziera C, Leppert D, Schlaeger R, Lieb J, Kuhle J, Swiss MS Cohort Study. Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. Ann Neurol 2022; 91:814-820.
Apr 9, 2022Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
Apr 9, 2022Ann Neurol 2022; 91:814-820
Oechtering Johanna, Lincke Therese, Schaedelin Sabine A, Décard Bernhard Friedrich, Maceski Aleksandra Maleska, Orleth Annette, Meier Stephanie, Willemse Eline A J, Buchmann Arabella, Khalil Michael, Derfuss Tobias, Benkert Pascal, Heijnen Ingmar A F M, Regeniter Axel, Müller Stefanie, Achtnichts Lutz, Lalive Patrice H, Salmen Anke, Pot Caroline, Gobbi Claudio, Kappos Ludwig, Granziera Cristina, Leppert David, Schlaeger Regina, Lieb Johanna Maria, Kuhle Jens, Swiss MS Cohort Study
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Urwyler P, Sendi P, Albrich W, Stüssi-Helbling M, Huber L, Bacci M, Camacho-Ortiz A, Sumer J, Thoma R, Trendelenburg M, Heijnen I, Moser S, Charitos P, Osthoff M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials 2021; 22:1.
Jan 4, 2021Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Jan 4, 2021Trials 2021; 22:1
Urwyler Pascal, Sendi Parham, Albrich Werner, Stüssi-Helbling Melina, Huber Lars C, Bacci Marcelo R, Camacho-Ortiz Adrián, Sumer Johannes, Thoma Reto, Trendelenburg Marten, Heijnen Ingmar A F M, Moser Stephan, Charitos Panteleimon, Osthoff Michael
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2015; 34:495-500.
Dec 28, 2015Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Dec 28, 2015J Clin Oncol 2015; 34:495-500
Taverna Christian, Zucca Emanuele, Heijnen Ingmar A F M, Rusterholz Corinne, Rondeau Stephanie, Biaggi Rudolf Christine, Lohri Andreas, Vorobiof Daniel A, Rauch Daniel, Raats Johann, Laszlo Daniele, Vanazzi Anna, Del Giglio Auro, Cevreska Lidija, Pabst Thomas, Mingrone Walter, Hitz Felicitas, Martinelli Giovanni, Ghielmini Michele